Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
Dana Miloslavich, Director Of Research at The Marketing Research Bureau Inc, shared on LinkedIn:
“The Marketing Research Bureau is pleased to announce the completion of the following report:
GLOBAL BLOOD AND PLASMA COLLECTIONS AND USE – 2023/2024
This new MRB report presents a global overview of blood collections and an analysis of all the sources of plasma used for fractionation from over 85 countries.
Plasma collection regulations and the historical context for those regulations are detailed in many countries, including plasma recovered from whole blood donations, as well as source plasma collected by public/non-profit entities and private companies.
Today, most of the plasma for fractionation is collected in the United States, but high collection costs constitute a cause of concern for those markets that largely depend on U.S. plasma.
Therefore, a good understanding of the potential for sourcing plasma from outside the U.S. is essential for planning and forecasting. In addition, awareness of plasma volumes collected in each individual country helps to inform both its current self-sufficiency level and quantities of imported plasma proteins needed to address its domestic market needs.
In addition to data on plasma for fractionation and whole blood collections, quantitative information on other blood components is included for those countries where such figures could be accessed.
Presented data are based on an extensive survey conducted by MRB in over 85 countries in 2023 and 2024. In addition to 2024 full-year figures for plasma fractionation, the report provides historical data going back 10 or more years as available”
Read more here.
More insights on Hemostasis Today.
-
Sep 14, 2025, 11:17Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
-
Sep 13, 2025, 13:32Beta Thalassemia Major After Splenectomy: Setareh Sheikhi Reports Striking nRBC Surge Reports Striking nRBC Surge
-
Sep 13, 2025, 13:26Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 14, 2025, 14:36Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
-
Sep 14, 2025, 12:37Ivan Budnik Highlights New Framework for Thrombus Resolution Analysis in Mouse IVC Stenosis Model
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 13:35Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
-
Sep 13, 2025, 13:20Giulia Simini: Our Review on the Hepatic Life Cycle of AAV is Now Available in JTH
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere